The oldest advice in the financial markets is to buy low and sell high. The trick to winning, however, is to find the right stocks to buy, and to remember that ‘buy low’ doesn’t always mean these stocks can’t go lower.
Sometimes the best bargains really do come in at the lowest prices. There are plenty of stocks under $10 that won’t break your bank and still offer substantial upside potential. How substantial? Well, the analysts at investment banking giant Oppenheimer have pinpointed two winners among these low-cost stocks, and they see the upside beginning at 200% or better.
What’s more, after using TipRanks’ database, we found out that both have scored enough positive reviews from the broader analyst community to earn a ‘Strong Buy’ consensus rating. Let’s see why these stocks are drawing plaudits across the board.
Corvus Pharmaceuticals (CRVS)
The first Oppenheimer pick we’re looking at is Corvus, a clinical-stage biopharmaceutical company focused on cancer treatment. The company’s approach is based on ITK inhibition, and its lead product candidate, CPI-818, also known as soquelitinib, acts as a selective ITK inhibitor with potential for treating both cancers and autoimmune/inflammatory diseases. The drug is an investigational, orally-administered small-molecule compound currently under clinical study for treating patients with T cell lymphoma.
Corvus has an active research pipeline featuring soquelitinib in three additional pre-clinical tracks. This drug candidate is wholly owned by Corvus and researched in-house. The firm also has two additional clinical-stage research tracks: ciforadenant and mupadolimab. These are under development in partnership agreements – ciforadenant with the KCRC and mupadolimab with Angel Pharmaceuticals, a Chinese partner.
In clinical updates, Corvus recently reported ongoing patient enrollment in the Phase 1/1b clinical trial of soquelitinib for relapsed TCL. Data released earlier this summer showed three complete responses and three partial responses out of 30 patients enrolled at the optimum dose of 200mg…